Hugo Philippeau

Hugo Philippeau

Auto-generated profile, based on publicly available information

Hugo Philippeau

Université de Montréal 1 Institute for Research in Immunology and Cancer Montréal, Québec, Canada

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2026 in Cancer Research
Verified
Journal Article
Closed access
LPLucas Porras
Lucas Porras
MCMarina Carrière
Marina Carrière
AGAnn-Sophie Gironne
Ann-Sophie Gironne
HPHugo Philippeau
Hugo Philippeau
GAGabriel Alzial
Gabriel Alzial
GDGeneviève Deblois
Geneviève Deblois
Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the histone methyltransferase complex polycomb repressive complex 2, is overexpressed and associated with a poor prognosis in triple-negative breast cancer (TNBC). Although EZH2 inhibition significantly alters chromatin landscapes and gene expression, it has a limited impact on the growth of TNBC models, suggesting adaptive compensatory mechanisms. In this study, we demonstrated that EZH2 inhibition causes the accumulation of misfolded proteins and double-stranded RNA, triggering an essential integrated stress response (ISR) through protein kinase R and protein kinase RNA–like endoplasmic reticulum kinase activation. By inducing ISR-mediated activating transcription factor 4 (ATF4), EZH2 inhibition enhanced amino acid flux and promoted glutaminolysis to support TNBC cell survival. Pharmacologic targeting of this metabolic axis with a glutaminase inhibitor in combination with EZH2 inhibition significantly impaired TNBC cell proliferation and tumor growth. These findings reveal a stress-driven metabolic adaptation that sustains TNBC survival upon EZH2 blockade and highlight the inhibition of this pathway as a strategy to enhance the efficacy of EZH2 inhibitors in TNBC. Significance: By inducing integrated stress response–ATF4-mediated metabolic rewiring, EZH2 inhibition creates a critical glutamine dependency in triple-negative breast cancer, exposing an actionable vulnerability through co-inhibition of glutaminase.